Contaminated Blood and Blood Products

Mark Garnier Excerpts

Thursday 14th October 2010 Commons Chamber

[Mark Garnier (Wyre Forest) (Con)]

It is a great pleasure to follow the hon. Member for Walsall South (Valerie Vaz).

I feel moved to speak today because this is an issue that shows how we as a society can show compassion for our fellow citizens and take responsibility for past mistakes. I have been well aware of the general topic of people suffering from contaminated blood transfusions for some time, but I did not become aware of either the full scale or the injustices of the problem until I met Ros Cooper, a constituent of mine, to whom I am incredibly grateful. She speaks with passion about this subject, and is an incredibly strong advocate for her fellow sufferers. She is relentless in her efforts to get her point across.

Ros’s story is not untypical. Diagnosed with a severe bleeding disorder at just six months, she has received blood products all her life. She receives them from as infrequently as three times a week to as often as twice a day. By the age of 14 she was able to inject herself with blood products. This is a woman who has had to grow up under the permanent threat of severe bleeding. Of course she has received treatment from the NHS, but as a direct result of that treatment she contracted hepatitis C—something she discovered only by hearsay, which seems to be a recurrent theme in this debate. Not only was she not given counselling to help her cope with that traumatic news, but she found out by hearsay that she might have been exposed to CJD.

Ros has received two rounds of treatment for her hepatitis C, but those, of course, are also traumatic. Six to 12 months of antiviral therapy can leave a patient unable to work: Ros was unable to earn a living for up to two years after both rounds of treatment. In the future she faces a liver transplant, cirrhosis or, worse still, cancer of the liver, as all sufferers of hepatitis C do. She is a vibrant young woman and would otherwise have faced a life that was admittedly severely inconvenienced—but still only inconvenienced—by her bleeding disorder. However, because she received contaminated blood products, arguably at a time when those providing them knew there was a risk of infection, she is severely disadvantaged.

Modern medicine has resulted in new types of manufactured blood products, reducing the risk to most patients. However, for Ros this salvation is not available. She suffers from a very rare disorder—type 3 von Willebrands—which means that she must receive real blood products that still come from America and overseas. So from between three times a week to up to twice a day, Ros injects herself with blood products that may carry an as yet undiscovered infection. Every time she feels exhausted or unwell, she will ask herself if she has infected herself with another illness. What is truly remarkable about Ros’s story is that she is clear of HIV, which is very welcome news.

The fact that we are having this debate is a significant leap forward, and I congratulate the hon. Member for Pontypridd (Owen Smith) on his efforts to move this incredibly important issue forward, and the hon. Member for Coventry North West (Mr Robinson) on taking up the banner. That it has taken so long for us to debate the matter, however, is a cause for concern, especially given the 4,670 people infected by hepatitis C and the 1,200 or so infected by HIV—infections that have resulted in nearly 1,800 deaths.

At the core of this debate are the findings and recommendations of the Archer review. To my mind, the eight recommendations are broadly reasonable, and I am amazed that some, such as free prescriptions, were not introduced a long time ago. However, I am grateful to the Minister for making a statement saying that that will be reviewed. Of course, there is always a sticking point—in this case, the level of compensation, which has now been even more confused by the amount of money that we are now discussing.

Some payments have already been made. In 2004 payments of £20,000, rising to £25,000 for more advanced stages of illnesses through hepatitis C, were made through the Skipton Fund. Other payments of a similar initial sum, rising to £60,000 on a needs assessment basis, plus ongoing payments, have been made through the MacFarlane Trust. However, those two systems illustrate that some form of uniformity needs to be established. If an individual’s life is blighted, irrespective of what is causing the blight, it is important to have uniformity of payout. I am very supportive of the Hepatitis C Trust’s recommendations that the Skipton Fund’s payout should be increased to the levels paid by the MacFarlane Trust.

I support the motion in full, but—I say this with a heavy heart—with one exception. When we talk about implementing the Archer report despite the intense financial pressure on the public purse, I am mindful that in just six days’ time my right hon. Friend the Chancellor of the Exchequer will deliver a statement that could make life-changing cuts to public expenditure. I cast an eye towards my many, many constituents, all of whom are extremely anxious about the comprehensive spending review, and I must act in the interests of all of them. It is vital that the victims of this tragedy should be allowed to live their lives as best they can—

[Penny Mordaunt]

My hon. Friend has mentioned the comprehensive spending review, but we should not forget that the health budget is ring-fenced and will be increased. We have also heard mention of the insurance industry and the companies that supplied blood products. I hope that he will join me in urging all Members to come forward with ideas to ensure the maximum compensation pot, whether that comes from public funds or, for example, from the £1 billion that exists in the insurance industry in orphan accounts. All Members should be contributing to that debate.

[Mark Garnier]

I welcome that intervention. It is incumbent on us all to work with Health Ministers to ensure that we find as much money as we can to help the victims. However, we have to be careful to ensure that compensation is not paid at the potential expense of many other special interest groups that need and deserve compensation and funding.

I am pleased that the Minister has said that the issue will be resolved, in one way or another, by the end of this year. I look forward to working with Members who have been affected by the contaminated blood scandal to ensure that the Minister comes up with a satisfactory response.